C

China Medical System Holdings Ltd
SWB:2M7C

Watchlist Manager
China Medical System Holdings Ltd
SWB:2M7C
Watchlist
Price: 1.51 EUR 2.72%
Market Cap: 6.2B EUR

China Medical System Holdings Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Medical System Holdings Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
C
China Medical System Holdings Ltd
SWB:2M7C
Pre-Tax Income
ÂĄ2B
CAGR 3-Years
-18%
CAGR 5-Years
-5%
CAGR 10-Years
5%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Pre-Tax Income
HK$2.4B
CAGR 3-Years
1%
CAGR 5-Years
9%
CAGR 10-Years
26%
U
United Laboratories International Holdings Ltd
HKEX:3933
Pre-Tax Income
ÂĄ3.8B
CAGR 3-Years
43%
CAGR 5-Years
36%
CAGR 10-Years
43%
Sino Biopharmaceutical Ltd
HKEX:1177
Pre-Tax Income
ÂĄ7.6B
CAGR 3-Years
-30%
CAGR 5-Years
6%
CAGR 10-Years
12%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Pre-Tax Income
HK$10.3B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Pre-Tax Income
$535m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
54%
No Stocks Found

China Medical System Holdings Ltd
Glance View

Market Cap
6.2B EUR
Industry
Pharmaceuticals

China Medical System Holdings Ltd., a prominent player in the pharmaceutical industry, weaves its business model around the intricate pathway of driving market expansion through innovation and strategic partnerships. Founded with a vision to bring cutting-edge and specialized medicines to the Chinese healthcare market, CMS has established itself as a stalwart distributor and marketer. The company operates by obtaining licenses and distribution rights for pharmaceutical products primarily from European and North American manufacturers. By leveraging these international partnerships, CMS effectively bridges the gap between Western innovation and Chinese demand, tailoring its portfolio to include niche and differentiated therapeutic products that cater to the evolving needs of China's healthcare landscape. At the core of CMS's revenue model lies its proficiency in brand building and market penetration. Unlike the conventional pharmaceutical giants focusing solely on R&D, CMS maximizes its profits through strategic marketing and efficient distribution networks. By prioritizing products that require expert promotion to healthcare professionals, CMS utilizes its extensive sales force to ensure these products gain maximum visibility and acceptance in the marketplace. This business model not only fosters a symbiotic relationship with international pharmaceutical partners but also sustains a robust pipeline of new offerings. Therefore, with a strategic balancing act between global pharmaceutical expertise and local market intricacies, China Medical System Holdings Ltd. continues to fortify its position as a pivotal conduit in the dissemination of specialized medical solutions across China.

2M7C Intrinsic Value
1.16 EUR
Overvaluation 23%
Intrinsic Value
Price
C

See Also

What is China Medical System Holdings Ltd's Pre-Tax Income?
Pre-Tax Income
2B CNY

Based on the financial report for Jun 30, 2025, China Medical System Holdings Ltd's Pre-Tax Income amounts to 2B CNY.

What is China Medical System Holdings Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
5%

Over the last year, the Pre-Tax Income growth was 17%. The average annual Pre-Tax Income growth rates for China Medical System Holdings Ltd have been -18% over the past three years , -5% over the past five years , and 5% over the past ten years .

Back to Top